BNO 0.00% 7.7¢ bionomics limited

BNO--29/5

  1. 4,330 Posts.
    BIONOMICS LIMITED 2002-05-29 ASX-SIGNAL-G
    ----------------------------------------------------------------------
    HOMEX - Adelaide
    ----------------------------------------------------------------------
    +++++++++++++++++++++++++
    Bionomics Limited (ASX:BNO), today announced progress of its product
    development collaboration with the European and US-based company
    Genmab A/S to create and develop fully human antibodies to
    angiogenesis targets identified by Bionomics.
    ----------------------------------------------------------------------
    Just two months into the collaboration, Bionomics' CEO and Managing
    Director, Deborah Rathjen said Bionomics and Genmab were progressing
    the development of antibody products by including a third Bionomics'
    target, one more than was initially proposed when the collaborative
    development deal was announced in March. Dr Rathjen also said that
    Bionomics and Genmab had formalized the steering and research
    committees that will manage the collaborative program.
    ----------------------------------------------------------------------
    "We are now on track to seeing a first antibody product entering
    clinical phase within twoyears," said Dr Rathjen. "The three targets
    that are subject to the joint development program include a target in
    a chromosomal region that is amplified in several human cancers,
    particularly in lung and liver tumours."
    ----------------------------------------------------------------------
    Industry estimates suggest that the treatment of lung cancer and
    liver cancer represent markets of at least US$2 billion each, on a
    global basis.
    ----------------------------------------------------------------------
    All three targets are associated with the process of angiogenesis,
    which is involved in the growth of cancer and inflammatory diseases.
    ----------------------------------------------------------------------
    "This is a very important partnership for Bionomics as the world
    antibody market is currently worth more than US$3 billion. Antibody
    products have shorter development times when compared with typical
    small molecule drug development. Working with Genmab will see
    Bionomics accelerate its product rollout from the lab to clinical use
    and human benefit," said Dr Rathjen.
    ----------------------------------------------------------------------
    FOR FURTHER INFORMATION PLEASE CONTACT:
    ----------------------------------------------------------------------
    Dr Deborah Rathjen
    CEO & MANAGING DIRECTOR
    Bionomics Limited
    Ph: +61 8 8354 6101
    ----------------------------------------------------------------------
    Or visit the Bionomics website at www.bionomics.com.au
    ----------------------------------------------------------------------
 
watchlist Created with Sketch. Add BNO (ASX) to my watchlist
(20min delay)
Last
7.7¢
Change
0.000(0.00%)
Mkt cap ! $41.94M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
4 339419 7.6¢
 

Sellers (Offers)

Price($) Vol. No.
7.9¢ 121349 3
View Market Depth
Last trade - 10.00am 23/01/2020 (20 minute delay) ?
(live)
Last
7.7¢
  Change
0.000 ( 1.05 %)
Open High Low Volume
7.7¢ 7.7¢ 7.7¢ 59708
Last updated 10.19am 23/01/2020 (live) ?
BNO (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.